- Home
- ENTA vs CRDF Comparison
ENTA vs CRDF Comparison
Compare ENTA & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- CRDF
- Stock Information
- Founded
- ENTA 1995
- CRDF 1999
- Country
- ENTA United States
- CRDF United States
- Employees
- ENTA N/A
- CRDF N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ENTA Health Care
- CRDF Health Care
- Exchange
- ENTA Nasdaq
- CRDF Nasdaq
- Market Cap
- ENTA 164.6M
- CRDF 144.4M
- IPO Year
- ENTA 2013
- CRDF N/A
- Fundamental
- Price
- ENTA $11.81
- CRDF $2.02
- Analyst Decision
- ENTA Strong Buy
- CRDF Strong Buy
- Analyst Count
- ENTA 5
- CRDF 5
- Target Price
- ENTA $20.20
- CRDF $11.10
- AVG Volume (30 Days)
- ENTA 1.1M
- CRDF 958.1K
- Earning Date
- ENTA 08-11-2025
- CRDF 11-06-2025
- Dividend Yield
- ENTA N/A
- CRDF N/A
- EPS Growth
- ENTA N/A
- CRDF N/A
- EPS
- ENTA N/A
- CRDF N/A
- Revenue
- ENTA $64,806,000.00
- CRDF $545,000.00
- Revenue This Year
- ENTA N/A
- CRDF N/A
- Revenue Next Year
- ENTA $1.65
- CRDF N/A
- P/E Ratio
- ENTA N/A
- CRDF N/A
- Revenue Growth
- ENTA N/A
- CRDF N/A
- 52 Week Low
- ENTA $4.09
- CRDF $1.90
- 52 Week High
- ENTA $15.28
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- ENTA 61.09
- CRDF 40.93
- Support Level
- ENTA $7.05
- CRDF $1.96
- Resistance Level
- ENTA $15.34
- CRDF $2.13
- Average True Range (ATR)
- ENTA 1.32
- CRDF 0.10
- MACD
- ENTA 0.47
- CRDF 0.03
- Stochastic Oscillator
- ENTA 53.86
- CRDF 32.61
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.